Hero image with Pittsburgh background pittplusme.org/study/1301

Pitt+Me HCC 18-037 – Relapsed or Refractory Multiple Myeloma

We're sorry. This study is closed and no longer recruiting participants.


Have you been diagnosed with multiple myeloma that has come back after treatment (relapsed) or that did not respond to treatment (refractory)? If so, you may be eligible to participate in a research study to help find the safest and most effective dose of an investigational drug called BION-1301. Eligible participants will receive BION-1301 every two weeks as an intravenous (IV) drug.

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe facebook twitter


This website is maintained by the Clinical and Translational Science Institute.
© Copyright 2018, University of Pittsburgh. All rights reserved.